An open-label study to determine the long-term safety, tolerability and biological activity of SAR421869 in patients with Usher syndrome Type 1B

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513500-34-00

Acronym

LTS13619

Enrollment

Registered

2024-09-12

Start date

2015-11-09

Completion date

Unknown

Last updated

2024-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Usher's syndrome

Brief summary

The incidence of adverse events

Detailed description

Clinically important changes in ocular safety assessments, Delay in retinal degeneration

Interventions

DRUGSAR421869

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The incidence of adverse events	—

Secondary

Measure	Time frame
Clinically important changes in ocular safety assessments, Delay in retinal degeneration	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026